Bosutinib is a potent (200 times imatinib) dual SRC/ABL kinase inhibitor that was approved for patients with CML with resistance or intolerance to imatinib, following the results of a phase I/II trial [52]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.